Ability Pharma Announces EMA-Orphan Drug Designation For ABTL0812 In Pancreatic Cancer
Barcelona (Catalonia, Spain), September 18, 2017. Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the European Medicines Agency (EMA) for the treatment of pancreatic cancer. This regulatory milestone comes after the ODD for ABTL0812 in pancreatic cancer by the FDA in December 2016, and the ODD for pediatric cancer neuroblastoma granted by EMA and FDA in 2015.
The ODD program of the EMA grants special status to medicines and biological products intended to treat, diagnose or prevent rare diseases, which affect less than 5 people every 10 000 in the European Union (EU). This designation establishes a period of exclusivity for seven years of commercialization against competition, as well as certain incentives, such as federal grants, tax credits, a decrease in regulatory fees in the drug approval process, and clinical development advice.
Pancreatic cancer is a life-threatening disease with a significant unmet medical need. The incidence of this cancer has markedly increased over the past several decades. Moreover, treatment options of pancreatic cancer are very limited due to its poor response to chemotherapy, radiation therapy and surgery as conventionally used.
In preclinical studies, ABTL0812 have shown efficacy in pancreatic cancer as single agent and synergistic effect (by 8 to 90 times) in combination with taxanes, platinum compounds and gemcitabine, with induction of tumor regression without increasing the toxicity associated with chemotherapy. First-line therapy in patients with either locally advanced or metastatic pancreatic cancer includes these compounds, and administered in combination with ABTL0812 could greatly improve the treatment outcome.
ABTL0812 is currently in phase 2 as first-line therapy in combination with chemotherapy in patients with endometrial or squamous lung cancer at Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Badalona and Girona), INCLIVA (Valencia) and Hospital Universitario Virgen del Rocio (Sevilla). The study will also include top leading centers in France.
"Receiving another Orphan Drug Designation for ABTL0812 is an important regulatory milestone achieved by AbilityPharma and an exciting step towards the clinical advancement of this first-in-class therapy," said Carles Domenech, PhD, CEO of Ability Pharmaceuticals. "We will continue to aggressively pursue our clinical development program with ABTL0812 for pancreatic cancer for the benefit of these patients, who currently have a short life expectancy once diagnosed”.
About ABTL0812
ABTL0812 causes cell death by autophagy through the overexpression of TRIB3, an endogenous Akt regulator. It is a first-in-class fully differentiated oral targeted anticancer compound inhibiting the PI3K/Akt/mTOR pathway without being a direct kinase inhibitor. Its unique mechanism of action was published at Clinical Cancer Research in December 2015.
In preclinical cancer models ABTL0812 is efficacious as single agent with an excellent safety profile in a broad spectrum of cancer types: lung, endometrial, pancreatic cancer and neuroblastoma. In these models the compound has also synergistic effect with chemotherapy (taxanes, platinum compounds and gemcitabine) without increasing its toxicity. ABTL0812 is also active on cells resistant to chemotherapy or other targeted
The ODD program of the EMA grants special status to medicines and biological products intended to treat, diagnose or prevent rare diseases, which affect less than 5 people every 10 000 in the European Union (EU). This designation establishes a period of exclusivity for seven years of commercialization against competition, as well as certain incentives, such as federal grants, tax credits, a decrease in regulatory fees in the drug approval process, and clinical development advice.
Pancreatic cancer is a life-threatening disease with a significant unmet medical need. The incidence of this cancer has markedly increased over the past several decades. Moreover, treatment options of pancreatic cancer are very limited due to its poor response to chemotherapy, radiation therapy and surgery as conventionally used.
In preclinical studies, ABTL0812 have shown efficacy in pancreatic cancer as single agent and synergistic effect (by 8 to 90 times) in combination with taxanes, platinum compounds and gemcitabine, with induction of tumor regression without increasing the toxicity associated with chemotherapy. First-line therapy in patients with either locally advanced or metastatic pancreatic cancer includes these compounds, and administered in combination with ABTL0812 could greatly improve the treatment outcome.
ABTL0812 is currently in phase 2 as first-line therapy in combination with chemotherapy in patients with endometrial or squamous lung cancer at Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Badalona and Girona), INCLIVA (Valencia) and Hospital Universitario Virgen del Rocio (Sevilla). The study will also include top leading centers in France.
"Receiving another Orphan Drug Designation for ABTL0812 is an important regulatory milestone achieved by AbilityPharma and an exciting step towards the clinical advancement of this first-in-class therapy," said Carles Domenech, PhD, CEO of Ability Pharmaceuticals. "We will continue to aggressively pursue our clinical development program with ABTL0812 for pancreatic cancer for the benefit of these patients, who currently have a short life expectancy once diagnosed”.
About ABTL0812
ABTL0812 causes cell death by autophagy through the overexpression of TRIB3, an endogenous Akt regulator. It is a first-in-class fully differentiated oral targeted anticancer compound inhibiting the PI3K/Akt/mTOR pathway without being a direct kinase inhibitor. Its unique mechanism of action was published at Clinical Cancer Research in December 2015.
In preclinical cancer models ABTL0812 is efficacious as single agent with an excellent safety profile in a broad spectrum of cancer types: lung, endometrial, pancreatic cancer and neuroblastoma. In these models the compound has also synergistic effect with chemotherapy (taxanes, platinum compounds and gemcitabine) without increasing its toxicity. ABTL0812 is also active on cells resistant to chemotherapy or other targeted